Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Global Blood Therapeutics, Inc. (GBT) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A FMR LLC reports a 0.4% stake in GLOBAL BLOOD THERAPEUTICS INC
10/17/2022 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
10/05/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/05/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/05/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/05/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/05/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/05/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/05/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/05/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/05/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/05/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/05/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/05/2022 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
10/05/2022 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
10/05/2022 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
10/05/2022 8-K Resignation/termination of a director
Docs: "First Supplemental Indenture, between Global Blood Therapeutics, Inc. and U.S. Bank Trust Company, National Association, as trustee"
10/05/2022 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
09/30/2022 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
09/23/2022 8-K Other Events  Interactive Data
09/23/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
09/12/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/31/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/29/2022 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
08/23/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/19/2022 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
08/18/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/18/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/10/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/08/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/08/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/08/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy